Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Prognostic and predictive factors for lung cancer

Marianne Paesmans
Breathe 2012 9: 112-121; DOI: 10.1183/20734735.006911
Marianne Paesmans
Institut Jules Bordet, Data Centre, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: marianne.paesmans@bordet.be
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Prognostic non-predictive marker.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Predictive non-prognostic biomarker.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    Prognostic and predictive biomarker.

Tables

  • Figures
  • Table 1 TNM classification (UICC, 7th edition, [7])
    StageTNMcTNM 5YpTNM 5Yc HRp HR
    0TisN0M0
    IAT1a, T1bN0M050%73%
    IBT2aN0M043%58%1.19, p = 0.0041.55, p<0.0001
    IIAT1a, T1b, T2a, T2bN1 N0M0 M036%46%1.23, p = 0.0021.44, p<0.0001
    IIBT2b, T3N1 N0M0 M025%36%1.46, p<0.00011.29, p<0.0001
    IIIAT1, T2, T3, T4N2 N1,2 N0,1M0 M0 M019%24%1.27, p<0.00011.47, p<0.0001
    IIIBT4, any TN2 N3M0 M07%9%1.54, p<0.00011.79, p<0.0001
    IVAny TAny NM1a, M1b2%13%1.64, p<0.00010.86, p = 0.10
    • T: tumour size (T1: ≤3 cm without bronchoscopic evidence of invasion more than proximal than the lobar bronchus; T1a: T1 ≤2 cm; T1b: T1 >2 cm and ≤ = 3 cm; T2: >3 cm and ≤7 cm or invasion of main bronchus, visceral pleura or associated with atelectasis or obstructive pneumonitis that extends to hilar region without extending to the whole lung; T2a: >3 cm and ≤5 cm; T2b: >5 cm and ≤7 cm; T3: >7 cm or invasion of chest wall, diaphragm, phrenic nerve, mediastinal pleura, parietal pericardum or tumour in the main bronchus without involvement of the carina or associated with atelectasis or obstructive pneumonitis that extends to the whole lung or separate tumour nodule in the same lobe; T4: tumour of any size with invasion of mediastinum or heart or great vessels or trachea or recurrent laryngeal nerve, oesophagus, vertebral body, carina or separate nodule in a different ipsilateral lobe). N: regional lymph node (N0: no regional lymph node metastasis; N1: metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intraplumonary node; N2: metastasis in ipsilateral mediastinal and/or subcarinal lymph node; N3: metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene or supraclavicular lymph nodes). M: distant metastasis (M0: no distant metastasis; M1: distant metastasis; M1a: separate nodules in a contralateral lobe, tumour with pleural nodules or malignant pleural or pericardial effusion; M1b: other distant metastasis). cTNM 5Y: rate of survival at 5 years when stage is clinically assessed; pTNM 5Y: rate of survival at 5 years when stage is pathologically assessed; cHR: hazard ratio for comparing overall survival of that clinical stage to the nearest less severe stage (for example cIB versus cIA or cIIIB versus cIIIA); pHR: hazard ratio for comparing overall survival of that pathological stage to the nearest less severe stage.

PreviousNext
Back to top
Vol 9 Issue 2 Table of Contents
Breathe: 9 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prognostic and predictive factors for lung cancer
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Prognostic and predictive factors for lung cancer
Marianne Paesmans
Breathe Dec 2012, 9 (2) 112-121; DOI: 10.1183/20734735.006911

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Prognostic and predictive factors for lung cancer
Marianne Paesmans
Breathe Dec 2012, 9 (2) 112-121; DOI: 10.1183/20734735.006911
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Introduction
    • Prognostic versus predictive factor
    • Prognostic factors
    • Predictive factors
    • Conclusions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Lung cancer
  • Respiratory clinical practice
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • A clinicians’ review of the respiratory microbiome
  • The problems of cohort studies
  • Breathing exercises for asthma
Show more Review

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society